The Role of Prostatic Arterial Embolization in Patients with Benign Prostatic Hyperplasia: A Systematic Review

详细信息    查看全文

• 作者：S. M. Schreuder ; A. E. Scholtens…
• 关键词：Prostate ; BPH ; Embolization ; Symptoms ; Quality of life ; Complications
• 刊名：CardioVascular and Interventional Radiology
• 出版年：2014
• 出版时间：October 2014
• 年：2014
• 卷：37
• 期：5
• 页码：1198-1219
• 全文大小：287 KB
• 参考文献：1. McVary KT (2006) BPH: epidemiology and comorbidities. Am J Manag Care 12(5 Suppl):S122–S128
  2. Rosen RC, Giuliano F, Carson CC (2005) Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 47(6):824-37 CrossRef
  3. Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173(4):1256-261 CrossRef
  4. Barry MJ, Fowler FJ Jr, O’Leary MP et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148(5):1549-557
  5. O’Leary MP (2000) LUTS, ED, QOL: alphabet soup or real concerns to aging men? Urology 56(5 Suppl):7-1 CrossRef
  6. American Urological Association Guideline: management of benign prostatic hyperplasia (BPH) (2010)
  7. Michel MC, Mehlburger L, Bressel HU et al (1998) Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 160(3 Pt 1):784-91
  8. McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338(9):557-63 CrossRef
  9. Rassweiler J, Teber D, Kuntz R et al (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management and prevention. Eur Urol 50(5):969-79 CrossRef
  10. Sun F, Sánchez FM, Crisóstomo V et al (2008) Benign prostatic hyperplasia: transcatheter arterial embolization as potential treatment—preliminary study in pigs. Radiology 246(3):783-89 CrossRef
  11. Jeon GS, Won JH, Lee BM et al (2009) The effect of transarterial prostate embolization in hormone-induced benign prostatic hyperplasia in dogs: a pilot study. J Vasc Interv Radiol 20(3):384-90 CrossRef
  12. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535 CrossRef
  13. Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529-36 CrossRef
  14. Pisco JM, Pinheiro LC, Bilhim T et al (2011) Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol 22(1):11-9 CrossRef
  15. Pisco JM, Rio Tinto H, Campos Pinheiro L et al (2013) Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol 23(9):2561-572 CrossRef
  16. Pisco J, Campos Pinheiro L, Bilhim T et al (2013) Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results. Radiology 266(2):668-77 CrossRef
  17. Rio Tinto H, Martins Pisco J, Bilhim T et al (2012) Prostatic artery embolization in the treatment of benign prostatic hyperplasia: short and medium follow-up. Tech Vasc Interv Radiol 15(4):290-93 CrossRef
  18. Bilhim T, Pisco J, Campos Pinheiro L et al (2013) Does polyvinyl alcohol particle size change the outcome of prostatic arterial embolization for benign prostatic hyperplasia? Results from a single-center randomized prospective study. J Vasc Interv Radiol 24(11):1595-602 CrossRef
  19. Bilhim T, Pisco J, Rio Tinto H et al (2013) Unilateral versus bilateral prostatic arterial embolization for lower urinary tract symptoms in patients with prostate enlargement. Cardiovasc Intervent Radiol 36(2):403-11 CrossRef
  20. Carnevale FC, da Motta-Leal-Filho JM, Antunes AA et al (2013) Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol 24(4):535-42 CrossRef
  21. Antunes AA, Carnevale FC, da Motta Leal Filho JM et al (2013) Clinical, laboratorial, and urodynamic findings of prostatic artery embolization for the treatment of urinary retention related to benign prostatic hyperplasia. A prospective single-center pilot study. Cardiovasc Intervent Radiol 36(4):978-86 CrossRef
  22. Bagla S, Martin CP, van Breda A et al (2014) Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 25(1):47-2 E-publication October 2013 CrossRef
  23. Bilhim T, Tinto HR, Fernandes L et al (2012) Radiological anatomy of prostatic arteries. Tech Vasc Interv Radiol 15(4):276-85 CrossRef
  24. Barry MJ (2001) Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 58(6 Suppl 1):25-2 discussion 32 CrossRef
  25. O’Leary MP, Wei JT, Roehrborn CG et al (2008) Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. BJU Int 101(12):1531-535 CrossRef
  26. Rosen RC, Cappelleri JC, Smith MD et al (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11(6):319-26 CrossRef
  
• 作者单位：S. M. Schreuder (1)
  A. E. Scholtens (1) (2)
  J. A. Reekers (1)
  S. Bipat (1)
  
  1. Department of Radiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
  2. Department of Radiology, Kennemer Gasthuis, Boerhaavelaan 22, 2035 RC, Haarlem, The Netherlands
  
• ISSN：1432-086X

文摘

Purpose This study was designed to summarize the evidence on clinical outcomes and complications of prostatic arterial embolization (PAE) in patients with benign prostatic hyperplasia (BPH). Methods We searched Medline and Embase for PAE trials of patients with BPH upto November 2013. Two reviewers independently checked the inclusion and exclusion criteria and performed data extraction of study characteristics, quantitative and qualitative outcomes, and complications. Results The search yielded 562 studies, of which 9 articles with 706 patients were included. In these 9 articles, there was a possible overlap of data and the quality of 8 studies was assessed as poor. All patients had moderate-to-severe, lower urinary tract symptoms (LUTS). The mean age ranged from 63.4-4.1?years. After embolization, a decrease of the prostate volume (PV) and post void residual (PVR) was seen mainly in the first month with a further decrease up to 12?months, increasing afterwards. The prostate specific antigen (PSA) decreased up to 3?months after PAE, increasing afterwards. The peak urinary flow (Qmax) increased mainly the first month and decreased after 30?months. The international prostate symptom score (IPSS) and quality of life-related symptoms (QOL) improved mainly during the first month, with a further improvement up to 30?months. No deterioration of the international index of erectile function (IIEF) was seen after PAE. The PAE procedure seems safe. Conclusions Although the number of studies was small, qualitatively poor, and with overlap of patients, the initial clinical outcomes as reported up to 12?months seem positive and the procedure seems safe.